Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply

Affiliations

¹ Toronto Centre for Liver Disease, Toronto, ON, Canada gideon.hirschfield@uhn.ca.
² University Hospital Zurich, Zurich, Switzerland.
³ University of Miami, Miami, FL.

Comment

Gideon M Hirschfield et al. N Engl J Med. 2024.

. 2024 May 30;390(20):1934-1935.

doi: 10.1056/NEJMc2403986.

¹ Toronto Centre for Liver Disease, Toronto, ON, Canada gideon.hirschfield@uhn.ca.
² University Hospital Zurich, Zurich, Switzerland.
³ University of Miami, Miami, FL.

No abstract available

Comment on

Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Francque SM, Heneghan MA, Invernizzi P, Jones D, Kruger FC, Lawitz E, Mayo MJ, Shiffman ML, Swain MG, Valera JM, Vargas V, Vierling JM, Villamil A, Addy C, Dietrich J, Germain JM, Mazain S, Rafailovic D, Taddé B, Miller B, Shu J, Zein CO, Schattenberg JM; ELATIVE Study Investigators’ Group; ELATIVE Study Investigators' Group. Kowdley KV, et al. N Engl J Med. 2024 Feb 29;390(9):795-805. doi: 10.1056/NEJMoa2306185. Epub 2023 Nov 13. N Engl J Med. 2024. PMID: 37962077 Clinical Trial.
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, Levy C, Villamil A, Ladrón de Guevara Cetina AL, Janczewska E, Zigmond E, Jeong SH, Yilmaz Y, Kallis Y, Corpechot C, Buggisch P, Invernizzi P, Londoño Hurtado MC, Bergheanu S, Yang K, Choi YJ, Crittenden DB, McWherter CA; RESPONSE Study Group. Hirschfield GM, et al. N Engl J Med. 2024 Feb 29;390(9):783-794. doi: 10.1056/NEJMoa2312100. Epub 2024 Feb 21. N Engl J Med. 2024. PMID: 38381664 Clinical Trial.